Literature DB >> 10344763

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

S Y Sun1, W Li, P Yue, S M Lippman, W K Hong, R Lotan.   

Abstract

The induction of apoptosis by the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has been documented in vitro in various cancer types. A role for reactive oxygen species (ROS) in apoptosis induced by 4HPR in some cancer cells has been demonstrated recently. We studied five different human head and neck and five lung cancer cell lines to determine whether the ROS play a general role in 4HPR-induced apoptosis. We found that 4HPR induced apoptosis in all of the cell lines; however, this effect was blocked by antioxidants in only 2 of the 10 cell lines. 4HPR induced a greater than 4-fold increase in the generation of intracellular ROS in these two cell lines compared with a much lower effect in other cell lines. Furthermore, these two cell lines were most sensitive to the induction of apoptosis by 4HPR. The level of the cellular antioxidant thiol and superoxide dismutase activity were relatively lower in cells, which responded to 4HPR with a high level of ROS generation. These results indicate that although ROS can mediate 4HPR-induced apoptosis in some cells, which may have a low endogenous cellular antioxidant levels, other mechanisms exist for 4HPR-induced apoptosis. One such mechanism may involve retinoic acid receptors (RARs) because an RAR antagonist was able to block partially 4HPR-induced apoptosis. In conclusion, 4HPR-induced apoptosis involves at least three different mechanisms, which are complex and can overlap in the same cell line: (a) one mechanism involving 4HPR-induced ROS; (b) one involving RARs; and (c) at least one that does not involve ROS or RARs and remains unclear.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344763

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors:  Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal:  Antioxid Redox Signal       Date:  2013-10-24       Impact factor: 8.401

2.  Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  Ruta D Rao; Melody A Cobleigh; Robert Gray; Mark L Graham; Larry Norton; Silvana Martino; George Thomas Budd; James N Ingle; William C Wood
Journal:  Med Oncol       Date:  2010-09-28       Impact factor: 3.064

Review 3.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.

Authors:  Aintzane Apraiz; Jolanta Idkowiak-Baldys; Naiara Nieto-Rementería; María Dolores Boyano; Yusuf A Hannun; Aintzane Asumendi
Journal:  Biochem Cell Biol       Date:  2012-03-19       Impact factor: 3.626

5.  Phase II trial of fenretinide in advanced renal carcinoma.

Authors:  Ulka Vaishampayan; Lance K Heilbrun; Ralph E Parchment; Vikash Jain; James Zwiebel; Ramesh R Boinpally; Patricia LoRusso; Maha Hussain
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

6.  Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Sharmin Khan; Shmuel Yaccoby
Journal:  Cancer Lett       Date:  2009-05-15       Impact factor: 8.679

7.  Investigation of the possible biological activities of a poisonous South African plant; Hyaenanche globosa (Euphorbiaceae).

Authors:  Saeideh Momtaz; Namrita Lall; Ahmed Hussein; Seyed Nasser Ostad; Mohammad Abdollahi
Journal:  Pharmacogn Mag       Date:  2010-02-13       Impact factor: 1.085

8.  Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Authors:  Vivian R Ruvolo; Kul B Karanjeet; Todd F Schuster; Rhoderick Brown; Yibin Deng; Edward Hinchcliffe; Peter P Ruvolo
Journal:  J Signal Transduct       Date:  2010-01-01

9.  Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice.

Authors:  Junya Fujimoto; Humam Kadara; Taoyan Men; Carolyn van Pelt; Dafna Lotan; Reuben Lotan
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

10.  Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.

Authors:  Kankan Wang; Hai Fang; Dakai Xiao; Xuehua Zhu; Miaomiao He; Xiaoling Pan; Jiantao Shi; Hui Zhang; Xiaohong Jia; Yanzhi Du; Ji Zhang
Journal:  PLoS One       Date:  2009-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.